AIM ImmunoTech Inc. (AIM) P/E Ratio History
Insufficient DataInsufficient historical P/E data to classify valuation. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of June 28, 2026, AIM ImmunoTech Inc. (AIM) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.31 and trailing twelve-month earnings per share of $-3.05.
Compared to the Healthcare sector median P/E of 23.0x, AIM trades at a 100% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, AIM trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AIM DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AIM Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
AIM P/E vs Peers
Vaccines and Infectious Disease peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $1B | 3.5Lowest | - | +307%Best | |
| $2B | 14.6 | - | -26% | |
| $131M | 7.7 | - | +150% | |
| $66B | 15.3 | 2.41 | +8% | |
| $317B | 17.6 | 0.83Best | +8% | |
| $444B | 106.1 | - | -1% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AIM — Frequently Asked Questions
Quick answers to the most common questions about buying AIM stock.
What is AIM's P/E ratio?
AIM ImmunoTech Inc. (AIM) trailing twelve-month P/E ratio is -0.0x, based on TTM diluted EPS of $-3.05. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is AIM stock overvalued or undervalued?
AIM current P/E: -0.0x. 5-year average P/E: N/A. Percentile: N/A.
Is AIM stock expensive?
AIM is fairly valued relative to its own history. The current P/E of -0.0x is near the 5-year average of N/A (N/A percentile of historical range).
What is AIM's historical P/E range?
Over the past 5 years, AIM's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of -0.0x places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does AIM's P/E compare to the S&P 500?
AIM current P/E: -0.0x. S&P 500 median P/E: 25.3x.
How does AIM's valuation compare to Healthcare peers?
AIM ImmunoTech Inc. P/E of -0.0x can be benchmarked against Healthcare peers in the comparison table on this page.
What is AIM's PEG ratio?
AIM PEG ratio is N/A, based on a P/E of -0.0x and EPS growth of 23.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is AIM's earnings yield?
AIM earnings yield is N/A, the inverse of its -0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.